News

Signant Health and Propeller Health are connecting their systems to help improve asthma and chronic obstructive pulmonary disease (COPD) patients’ adherence to inhaled medication and symptom control. Signant said it will connect its TrialMax electronic clinical outcome assessment (eCOA) platform to Propeller’s digital health platform for…

Verona Pharma announced positive top-line results on the use of nebulized ensifentrine as an add-on to tiotropium (Spiriva Respimat) in people with moderate-to-severe chronic obstructive pulmonary disease (COPD). The results come from a Phase 2b clinical trial (NCT03937479), which showed that ensifentrine — when…

New York cardiopulmonary physical therapist Noah Greenspan has launched the Pulmonary Wellness Foundation (PWF), a nonprofit group that provides free online information on a range of prevalent, rare and ultra-rare pulmonary diseases for those who can’t afford to pay for it. PWF specifically targets patients with pulmonary fibrosis,…

A new double-combination therapy that promotes lung expansion and airway clearance has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of people with lung diseases including chronic obstructive pulmonary disease (COPD) and asthma. The therapy was developed by the Monaghan Medical Corporation  and combines two…

Cancer therapies blocking specific protein receptors called ErbB reduced inflammation in animal models of inflammatory diseases — including those affecting the lung — by destroying neutrophils, a type of immune cell, a preclinical study found. According to the researchers, these findings suggest that treatments blocking the activity…

A newly developed assisted breathing device, based on the principles of older mechanical respirators but with more convenience and power, may soon be available for people with lung diseases who have trouble breathing. The Right Air vest is a small, powerful device to assist breathing that can be used…

AstraZeneca’s triple-combination therapy for people with chronic obstructive pulmonary disease (COPD) has been approved in China as a maintenance treatment. The therapy comprises three compounds: the corticosteroid budesonide, and two long-acting bronchodilators — glycopyrronium, a muscarinic antagonist, and formoterol fumarate, a β2-agonist. This combo…

Using e-cigarettes significantly increases the risk of developing chronic lung diseases like asthma, bronchitis, emphysema, and chronic obstructive pulmonary disease (COPD), a study found. Dual users — those who smoke tobacco and use e-cigarettes — are at an even higher risk than people with only one of these habits.

The use of Propeller Health’s digital health program, which integrates real-time data from chronic obstructive pulmonary disease (COPD) patients and feedback from healthcare providers, had a significant improvement on health outcomes, a new study shows. The study, “Passive Monitoring of Short-Acting Beta-Agonist Use via Digital Platform in…

CSA Medical‘s RejuvenAir System has been granted CE Mark approval in Europe for treating people with chronic obstructive pulmonary disease (COPD) who have chronic bronchitis — frequent inflammation of the bronchial airways. RejuvenAir is a cryosurgical medical device designed to destroy cells on the surface of the…